Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy
To determine whether neurturin (NTN), a recently identified homologue of glial cell line-derived neurotrophic factor (GDNF), is able to preserve tyrosine hydroxylase immunoreactivity (TH-IR) in a rat model of Parkinson's disease, polymer encapsulated cells genetically engineered to release NTN were implanted near the substantia nigra 1 week before a unilateral medial forebrain bundle axotomy. Animals were allowed to survive for 1 week post-axotomy. Upon sacrifice, animals that received a NTN capsule had a significantly higher percentage of TH-IR (lesioned side vs non-lesioned side) than animals that had received a capsule containing non-transfected parent cells. However, in contrast to GDNF, no reduction of turning was observed upon amphetamine rotation with NTN. Nevertheless, these results suggest that NTN might have a therapeutic value for the treatment of Parkinson's disease.
Keywords: Analysis of Variance ; Animals ; Axotomy ; Cell Line ; Cricetinae ; Dopamine/ physiology ; Female ; Immunohistochemistry ; Nerve Growth Factors/ pharmacology ; Neurons/ drug effects ; Neuroprotective Agents/ pharmacology ; Neurturin ; Prosencephalon/ drug effects/surgery ; Rats ; Rats ; Wistar ; Tyrosine 3-Monooxygenase/analysis
Division of Surgical Research and Gene Therapy Center, CHUV, Lausanne, Switzerland.
Record created on 2007-03-09, modified on 2016-08-08